null Ramy Saleh, MD, M.Sc., FRCPC

Associate Investigator, RI-MUHC , Glen site

Cancer Research Program

Assistant Professor, Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University



medical oncology • phase I • clinical trials • GU malignancies • sarcoma

Research Focus

My main research focus is on early-stage clinical trials (phases 1 and 2) and testing new medications in cancer patients for the first time. My goal is to bring cutting-edge medications to metastatic cancer patients and provide them with new and extra treatments in their fight against cancer. In addition, my academic interests include quality improvement in the medical field, with a focus on medical oncology. This involves enhancing work efficiency while increasing patient safety and reducing costs to the healthcare system. For the last ten years I have been heavily involved in creating medical platforms to address those needs and, at the same time, link multiple systems together to reduce the burden on healthcare professionals.

Selected Publications

Click on Pubmed to see my current publications list

  • Saleh RR, Meti N, Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir A. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. Cancer Med. 2020 Sep. PMID: 32886422.

  • Saleh RR, Nadler MB, Desnoyers A, Rodin DL, Abdel-Qadir H, Amir E. Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group. Sci Rep. 2020;10(1): 1-7. PMID: 32139756.

  • Saleh RR, Peinado P, Fuentes-Antras J, Perez-Segura P, Pandiella A, Amir E, Ocana A. Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. Frontiers in Oncology. 2019;9: 1040. PMID: 31681578.

  • Saleh RR, Majeed H, Tibau A, Booth C, Amir E. Undisclosed Financial Conflicts of Interest among Authors in the American Society of Clinical Oncology Clinical Practice Guidelines. Cancer. 2019 Nov 15;125(22):4069-4075. PMID: 31355923.

  • Saleh RR, Fuentes-Antras J, Peinado P, Perez-Segura P, Amir E, Ocana A. Prognostic Value of Receptor Tyrosine Kinase-like Orphan Receptor (ROR) Family in Cancer: A Meta-analysis. Cancer Treatment Reviews. 2019 Jul; 77:11-19. PMID: 31174180.